
NUTX Stock Forecast & Price Target
NUTX Analyst Ratings
Bulls say
Nutex Health is poised for continued growth with its de novo pipeline and plans to add at least 10 hospitals by 2028, driven by consolidation and partnerships in the industry, and a focus on non-Certificate of Need states. With the recent court ruling in TMA III, we expect less arbitration and a more accurate payment mechanism, leading to increased collections and a positive impact on revenue and profitability. Despite potential reimbursement cuts from government regulation, Nutex's strong track record and robust revenue stream from its hospital division contribute to a compelling valuation at 6x forward EV/EBITDA with a potential target of $306 in the near term.
Bears say
Nutex Health is a physician-led healthcare company with a negative outlook due to several factors. These include a shortage of qualified personnel, exposure to arbitration/litigation/collection, potential litigation risk, high governance and key person risk, and execution and financing risk. Additionally, Nutex's valuation seems expensive at 4x FY27 EBITDA compared to industry peers' average of 9x. Its IDR process may also be impacted by competition from other companies, and its capital-light strategy is dependent on timely and cost-effective development of new facilities and favorable market conditions for sale-leasebacks. Overall, these factors could result in missed revenue and earnings forecasts and limit the company's growth potential.
This aggregate rating is based on analysts' research of Nutex Health Inc and is not a guaranteed prediction by Public.com or investment advice.
NUTX Analyst Forecast & Price Prediction
Start investing in NUTX
Order type
Buy in
Order amount
Est. shares
0 shares